NCT05957367 - A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions

GIST

Interventions

DRUG

Inlexisertib

Oral Tablet Formulation

DRUG

Ripretinib

Oral Tablet Formulation

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center - Main Campus, New York

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

22031

RECRUITING

Virginia Cancer Specialist, PC, Fairfax

33136

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

44195

RECRUITING

Cleveland Clinic Taussig Cancer Center, Cleveland

49546

RECRUITING

START Midwest, Grand Rapids

63110

RECRUITING

Washington University School of Medicine - Siteman Cancer Center, St Louis

90033

RECRUITING

University of Southern California - Norris Comprehensive Cancer Center, Los Angeles

90095

RECRUITING

UCLA Department of Medicine-Hematology/Oncology, Los Angeles

97239

RECRUITING

Oregon Health & Science University, Portland